References
- Saltiel AR. Second messengers of insulin action. Diabetes Care 1990;13:244–56
- Nestler JE, Jakubowicz DJ, Reamer P, . Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–20
- Genazzani AR, Lanzoni C, Ricchieri F, . Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–44
- Sowers JR, Epstein M, Froholich ED. Diabetes, hypertension, and cardiovascular disease. An update. Hypertension 2001;37: 1053–9
- Giordano D, Corrado F, Santamaria A, . Effects of myo- inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause 2011;18:102–4
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
- Haffner SM, Miettinem H, Stern MP. The homeostasis model in the San Antonio Heart study. Diabetes Care 1997;20:1087–92
- De Micheli A. Italian standards for diabetes mellitus 2007: executive summary: Diabete Italia, AMD Associazione Medici Diabetologi, SID Società Italiana di Diabetologia. Acta Diabetol 2008, 29 Mar
- Roeters van Lennep JE, Westerveld HT, Erkelens DW, . Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002;53:538–49
- Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: The Rancho Bernardo Study 1984–1991. Am J Epidemiol 1994;140:857–69
- Hu G, Qiao Q, Tuomilehto J, . Prevalance of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066–76
- Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008;196:489–96
- Wilson PW, D’Agostino RB, Levy D, . Prediction of coronary heart disease using risk factor categories. Circulation 1998;97: 1837–47
- Gupta AK, Smith SR, Greenway L, . Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009;11:330–7
- Esposito K, Ciotola M, Carleo D, . Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006;29: 1071–6
- Fontbonne A, Diouf I, Baccara-Dinet M, . Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab 2009;35:385–91
- Baillargeon J-P, Iuorno MJ, Apridonidze T, . Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010;8:127–36